Professional
Added to YB: 2025-08-21
Pitch date: 2025-06-30
HALO [neutral]
Halozyme Therapeutics, Inc.
+20.14%
current return
Author Info
No bio for this author
Company Info
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
Market Cap
$8.3B
Pitch Price
$51.78
Price Target
N/A
Dividend
N/A
EV/EBITDA
11.07
P/E
14.83
EV/Sales
7.32
Sector
Biotechnology
Category
special_situation
Meridian Growth Fund Portfolio Holding: Halozyme Therapeutics, Inc.
HALO trimmed position: Drug delivery platform with ENHANZE tech enables subcutaneous biologics in minutes vs hours of IV infusion. Stock down as CMS may reclassify ENHANZE drugs, subjecting them to earlier Medicare price negotiations. Still offers fewer injection reactions & major time/cost savings for clinics.
Read full article (1 min)